ADA issues recommendations to improve insulin access

On the heels of a white paper calling attention to the limited accessibility and escalating cost of insulin, the American Diabetes Association (ADA) is now offering specific policy recommendations to address the problem.

On the heels of a white paper calling attention to the limited accessibility and escalating cost of insulin, the American Diabetes Association (ADA) is now offering specific policy recommendations to address the problem. The online statement focuses on four primary goals, including improved pricing transparency on the part of insulin makers, wholesalers, PBMs, pharmacies, and health plans. ADA also advocates for a streamlined approval process for biosimilar insulins, as there are just two currently available, and encourages FDA to continue to encourage competition on this front. Additionally, the organization wants government and private health insurers to amend their prescription drug benefit plans to cover insulin without patient cost-sharing. Barring complete elimination, ADA believes cost-sharing should at least be presented as a flat dollar amount to create consistency and manageability for the consumer. The fourth major point that ADA drives home is that access to health care coverage should be widened for all patients with diabetes.